8-K: GRAIL Reports Strong Galleri Sales, Key Trial Results

GRAIL, Inc. announced its Q4 and full-year 2025 financial results, alongside topline data from the NHS-Galleri trial and PATHFINDER 2 study, highlighting significant commercial growth and progress in multi-cancer early detection.

Summary

• Total revenue for the fourth quarter of 2025 grew 14% year-over-year to $43.6 million.
• U.S. Galleri revenue for the fourth quarter of 2025 grew 31% year-over-year to $41.3 million.
• Full year 2025 total revenue increased 17% year-over-year to $147.2 million, with U.S. Galleri revenue growing 26% to $136.8 million.
• Over 185,000 Galleri tests were sold in 2025.
• Net loss for Q4 2025 was $99.2 million, and for the full year 2025, it was $408.4 million.
• The Premarket Approval (PMA) submission for Galleri to the FDA was completed in January.
• Topline results from the NHS-Galleri trial showed a substantial reduction in Stage IV cancer diagnoses and a four-fold higher cancer detection rate, though the primary endpoint of statistically significant combined Stage III-IV reduction was not met.
• Analysis of the full 35,000 participant PATHFINDER 2 study was completed, demonstrating consistent performance and a strong safety profile.
• The company maintains a strong financial position with $904.4 million in cash, cash equivalents, and short-term marketable securities as of December 31, 2025, providing cash into 2030.
• The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act became federal law, establishing a Medicare coverage pathway for multi-cancer early detection tests.
• Galleri access expanded through digital health platforms including Hims & Hers, Function Health, and Everlywell.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a largely positive update, driven by strong commercial growth, a significant capital raise, and the establishment of a Medicare coverage pathway. While the primary endpoint miss in the NHS-Galleri trial is a notable setback, the strong secondary endpoints, particularly the reduction in Stage IV diagnoses, still represent a substantial clinical benefit and market opportunity.

Positives

• Strong revenue growth: Q4 total revenue up 14% YoY to $43.6 million; full year total revenue up 17% YoY to $147.2 million.
• Significant U.S. Galleri revenue growth: Q4 up 31% YoY to $41.3 million; full year up 26% YoY to $136.8 million.
• High test volume: Sold over 185,000 Galleri tests in 2025.
• Improved gross loss: Q4 gross loss improved by 30% to $11.1 million; full year gross loss improved by 20% to $62.6 million.
• Improved Adjusted EBITDA: Q4 Adjusted EBITDA improved by 15% to $(71.8) million; full year Adjusted EBITDA improved by 34% to $(320.6) million.
• Strong cash position: $904.4 million in cash, cash equivalents, and short-term marketable securities as of December 31, 2025, extending cash runway into 2030.
• Successful capital raise: Raised over $435 million, providing financial flexibility.
• PMA submission completed: Final module of Premarket Approval (PMA) application for Galleri submitted to the FDA in January.
• Positive NHS-Galleri trial results: Substantial reduction in Stage IV cancer diagnoses, increased Stage I and II detection of deadly cancers, and a four-fold higher overall cancer detection rate compared to standard of care alone. No serious safety concerns reported.
• PATHFINDER 2 study completion: Full analysis of 35,000 participants completed, demonstrating consistent performance and strong safety profile.
• Medicare coverage pathway established: The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act became federal law.
• Expanded market access: Galleri now available through digital health platforms like Hims & Hers, Function Health, and Everlywell.

Negatives

• Continued net loss: Q4 net loss of $99.2 million; full year net loss of $408.4 million.
• NHS-Galleri trial primary endpoint missed: The trial did not meet the primary endpoint of a statistically significant reduction in combined Stage III and IV cancers, although a favorable trend was observed.
• Higher than anticipated incidence of Stage III cancers in the NHS-Galleri trial.
• Gross loss remains negative: $11.1 million in Q4 and $62.6 million for the full year.

Risks

• Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially and adversely.
• Factors and numerous associated risks are discussed under the section entitled 'Risk Factors' in the Annual Report on Form 10-K for the period ended December 31, 2025 (and Form 10-K for 2024 and 10-Q for Q3 2025 for Exhibit 99.2).
• Operating in a dynamic and rapidly changing environment where new risks emerge from time to time.
• Management cannot predict all risks or assess the impact of all factors on the business.
• Inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the company's control.
• Cannot guarantee future results, level of activity, performance, or achievements.
• Actual results, financial condition, and success in business strategies and operations may differ materially from those indicated in forward-looking statements.
• The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider.
• A test result of 'No Cancer Signal Detected' does not rule out cancer.
• A test result of 'Cancer Signal Detected' requires confirmatory diagnostic evaluation by medically established procedures.
• False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur.
• The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration.
• The applicability of the NHS-Galleri results to the commercial or FDA versions of the Galleri test.
• Expectations or timelines relating to the approval of Galleri by the FDA, if at all.

Future Outlook

GRAIL anticipates continued commercial growth in 2026, driven by new and expanding partnerships in digital health and further integration into health systems. The company plans to present detailed results from both the PATHFINDER 2 and NHS-Galleri trials in mid-2026, with full data from PATHFINDER 2 to be submitted for presentation at a conference later this year and detailed NHS-Galleri results at the ASCO 2026 Annual Meeting. GRAIL is also expanding its field-based sales and medical teams to support growing demand and plans to extend the NHS-Galleri trial's follow-up period by 6-12 months for additional analysis.

Management Comments

• "2025 was a year of significant commercial growth for GRAIL, and we're excited by the building momentum for multi-cancer early detection." Bob Ragusa, Chief Executive Officer at GRAIL.
• "Our teams completed Galleri's PMA submission to the FDA in January. And today, we announced topline results for the NHS-Galleri trial and completion of the analysis of the full 35k participant PATHFINDER 2 study. We remain on track for continued commercial growth in 2026 with new and expanding partnerships in digital health and further integration into health systems." Bob Ragusa, Chief Executive Officer at GRAIL.
• "The NHS-Galleri trial provides the strongest evidence to date that multi-cancer early detection can shift the stage at which cancers are detected at a population level. We are excited to see the substantial reduction in Stage IV cancer diagnoses, as well as the continued strong Galleri test performance metrics. Based on these promising data, as well as the exciting PATHFINDER 2 results, we are expanding our field-based sales and medical teams to bolster our education efforts and support growing demand." Bob Ragusa, Chief Executive Officer at GRAIL.
• "As an oncologist, I see how profound the difference is between Stage III and Stage IV disease... Reducing the proportion of patients diagnosed with metastatic disease is therefore not merely a statistical aim, it dramatically increases the number of patients for whom eradication of disease and cure is possible." Professor Charles Swanton, thoracic medical oncologist at University College Hospital, London and one of the NHS-Galleri trials chief investigators.
• "The reduction in Stage IV cancer diagnoses is an exciting and critically important outcome, which we believe can lead to more effective intervention for patients, particularly given the substantial and growing arsenal of effective treatments for many Stage III cancers." Sir Harpal Kumar, Chief Scientific Officer and President, International at GRAIL.

Industry Context

StockSavvy.ai notes that the multi-cancer early detection (MCED) market is rapidly evolving, with GRAIL's Galleri test positioned as a leader. The establishment of a Medicare coverage pathway for MCED tests signifies growing regulatory and payer acceptance, a critical step for broader adoption. The expansion into digital health platforms reflects a broader industry trend towards consumer-centric healthcare access and telemedicine integration for diagnostic services.

Comparison to Industry Standards

• Galleri is stated to be the only available MCED test with demonstrated performance in patients screened for cancer.
• Claims to have the lowest false positive rate of any MCED test on the market.
• Increases cancer detection seven-fold when added to recommended screenings for breast, cervical, colorectal, and lung cancers.
• The NHS-Galleri trial is described as the first and largest prospective, randomized, controlled trial to assess the clinical utility and performance of a multi-cancer early detection test for population screening when added to standard care.

Legal Proceedings

• Illumina/GRAIL merger & divestiture legal and professional services costs were incurred, associated with the acquisition and corresponding antitrust litigation, including compliance with hold separate arrangements imposed by the European Commission, and legal and professional services costs associated with the divestiture.

Stakeholder Impact

• Shareholders: Potential for increased value due to commercial growth, strong cash position, and progress towards FDA approval and Medicare coverage. However, continued net losses and the primary endpoint miss in the NHS-Galleri trial introduce uncertainty.
• Patients: Improved access to multi-cancer early detection through Galleri, potentially leading to earlier diagnosis and better treatment outcomes, especially with the reduction in Stage IV diagnoses.
• Healthcare Providers: New tool for early cancer detection, supported by clinical trial data, which could integrate into standard care.
• Employees: Expansion of sales and medical teams suggests job growth and stability.

Next Steps

• Continued commercial growth in 2026 with new and expanding partnerships in digital health.
• Further integration into health systems in 2026.
• Presenting detailed results from PATHFINDER 2 and NHS-Galleri trial in mid-2026.
• Submitting full PATHFINDER 2 data for presentation at a conference later this year.
• Submitting detailed NHS-Galleri results for presentation at the ASCO 2026 Annual Meeting.
• Expanding field-based sales and medical teams to bolster education efforts and support growing demand.
• Additional analyses are underway to better understand the rich data from the NHS-Galleri trial.
• Plans to extend the NHS-Galleri trial's follow-up period by 6-12 months.

Key Dates

Recommendation

GRAIL demonstrates strong commercial momentum and significant progress in regulatory and clinical fronts, including a completed PMA submission and positive secondary endpoints from the NHS-Galleri trial. The substantial cash position provides a long runway. However, the miss on the primary endpoint of the NHS-Galleri trial introduces a notable clinical and market uncertainty. While the reduction in Stage IV cancers is clinically meaningful, the failure to achieve statistical significance for combined Stage III-IV reduction could impact broader adoption and reimbursement decisions. Investors should hold, awaiting further detailed trial data and FDA approval outcomes to assess the long-term market penetration and profitability potential.

Keywords

Multi-cancer early detection, Galleri, cancer screening, FDA PMA, NHS-Galleri trial, PATHFINDER 2, financial results, diagnostics, liquid biopsy, GRAL, healthcare technology